The Cost and Outcome of Treatment of Patients Admitted with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Shiraz, Southern Iran

Author:

Emadi Mehrnoosh1,Taheri Mohammad Hossein1,Keshavarz Khosro1,Masoompour Seyed Masoom1

Affiliation:

1. Shiraz University of Medical Sciences

Abstract

Abstract Background Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) decreases lung function and quality of life, and is the main driver of the costs of chronic obstructive pulmonary disease (COPD), the treatment of which in hospital is highly expensive. The present study aimed at determining the costs and outcomes of treatment of the patients hospitalized with AECOPD in Shahid Faqihi Hospital in Shiraz in 2021. Methods The present cost-outcome analysis was conducted as a descriptive-analytical, retrospective study. The research tool was a researcher-made form prepared and used to extract the patients' demographic and clinical information as well as the outcome and direct and avoidable medical costs, after consultations with some experts. In order to analyze the collected data, descriptive and inferential statistics indicators (t-tests with two independent groups and analysis of variance) were used and the data were analyzed using Excel and SPSS23 statistical software. Results Most of the studied patients were male (70.7%), and 81.3% of the patients had comorbidities. Besides, 76% of the patients had experienced disease exacerbation at most twice a year and 69.3% had been hospitalized < 7 times in the last year. The total average direct and avoidable medical costs were $2620 and $754, respectively. The financial burdens of avoidable antibiotics, stay, ICU, and lung CT scan in 2021 were $1,501, $3,244, $869, and $1,856, respectively. Of all the patients, 80.6% were discharged with full recovery, 7.3% were transferred to ICU, and 10.7% died. The number of hospitalization days, the use of other drugs, and AECOPD with brain disease had a significant effect on the patients’ total medical costs (p < 0.01). Conclusion Prevention of AECOPD, especially moderate or severe ones, is potentially cost-effective. Given that exacerbations can impose a large financial burden on patients and insurers, they will certainly lead to resource loss and prevent the resources from being allocated to effective interventions. Therefore, the use of effective clinical guidelines seems necessary to prescribe avoidable services to patients with AECOPD.

Publisher

Research Square Platform LLC

Reference69 articles.

1. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease;Ozkaya S;ClinicoEconomics and Outcomes Research,2011

2. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial;Ries AL;Am J Respir Crit Care Med,2003

3. WORLD HEALTH ORGANIZATION., The top 10 causes of death 2019 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

4. Projections of global mortality and burden of disease from 2002 to 2030;Mathers CD;PLoS Med,2006

5. Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2020 [Available from: www.goldcopd.org.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3